For qualified investors in Switzerland

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies


EUR 40.28
As of 25/11/2020

1-Day Change
EUR -0.02 (-0.05%)
As of 25/11/2020

Morningstar Rating

Morningstar ratings are based on the representative share class of this fund and are dated to the last month-end upon availability from Morningstar.


Navigate Uncertainty

Watch now for a current market perspective and outlook from the investment team


The Fund aims to provide capital growth over the long term.
Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.


The Fund invests in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country.
The Fund may also invest in other assets including cash and money market instruments.
The investment manager may use derivatives (complex financial instruments) to reduce risk, to manage the Fund more efficiently, or to generate additional capital or income for the Fund.
The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund’s performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.


The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is for promotional purposes and does not qualify as an investment recommendation.


  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care
Past performance is not a guide to future performance. 


Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.


Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Cumulative & Annualised Performance (%)
As of 31/10/2020
A2 HEUR (Net) MSCI World Health Care
  Cumulative Annualised
1MO YTD 1YR 3YR 5YR 10YR Since Inception
A2 HEUR (Net) -1.99% 5.12% 17.58% 8.84% 5.24% 13.53% 6.56%
MSCI World Health Care -4.93% -0.97% - - - - -
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 30/06/2020)


Top Holdings (As of 31/10/2020)
UnitedHealth Group Inc 3.47
Merck & Co Inc 3.39
Thermo Fisher Scientific Inc 3.21
AbbVie Inc 3.03
Novartis AG (ADR) 3.02
Roche Holding AG 2.90
AstraZeneca PLC 2.85
Abbott Laboratories 2.47
Humana Inc 2.45
Bristol-Myers Squibb Co 2.24
Total 29.03
Sector Allocation % OF FUND % OF FUND (As of 31/10/2020)
Health Care 99.89
Cash & Equivalents 0.11
Regional Allocations % OF FUND % OF FUND (As of October 31, 2020)
North America 82.04
Europe 16.03
Japan 1.29
Asia/Pacific Ex Japan 0.53
Cash & Equivalents 0.11


  • The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • Past performance is not a guide to future performance.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
  • The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.